122 related articles for article (PubMed ID: 11878185)
1. Soft cannabinoid analogues as potential anti-glaucoma agents.
Buchwald A; Derendorf H; Ji F; Nagaraja NY; Wu WM; Bodor N
Pharmazie; 2002 Feb; 57(2):108-14. PubMed ID: 11878185
[TBL] [Abstract][Full Text] [Related]
2. Soft cannabinoid analogues as potential anti-glaucoma agents.
Buchwald A; Browne CE; Wu WM; Ji F; Bodor N
Pharmazie; 2000 Mar; 55(3):196-201. PubMed ID: 10756540
[TBL] [Abstract][Full Text] [Related]
3. [Possibilities of applying cannabinoids' in the treatment of glaucoma].
Nadolska K; Goś R
Klin Oczna; 2008; 110(7-9):314-7. PubMed ID: 19112869
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids in glaucoma II: the effect of different cannabinoids on intraocular pressure of the rabbit.
ElSohly MA; Harland EC; Benigni DA; Waller CW
Curr Eye Res; 1984 Jun; 3(6):841-50. PubMed ID: 6329602
[TBL] [Abstract][Full Text] [Related]
5. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA
Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127
[TBL] [Abstract][Full Text] [Related]
6. The effects of prostacyclin and its stable analog on intraocular pressure.
Hoyng PF; Groeneboer MC
Prog Clin Biol Res; 1989; 312():369-78. PubMed ID: 2508128
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.
de Leval X; Ilies M; Casini A; Dogné JM; Scozzafava A; Masini E; Mincione F; Starnotti M; Supuran CT
J Med Chem; 2004 May; 47(11):2796-804. PubMed ID: 15139757
[TBL] [Abstract][Full Text] [Related]
9. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
Curr Eye Res; 2009 Apr; 34(4):282-6. PubMed ID: 19373576
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma.
Crandall J; Matragoon S; Khalifa YM; Borlongan C; Tsai NT; Caldwell RB; Liou GI
Ophthalmic Res; 2007; 39(2):69-75. PubMed ID: 17284931
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effect of hypertonic hydroxyethyl starch and mannitol on the intraocular pressure in healthy normotensive dogs and the effect of hypertonic hydroxyethyl starch on the intraocular pressure in dogs with primary glaucoma.
Volopich S; Mosing M; Auer U; Nell B
Vet Ophthalmol; 2006; 9(4):239-44. PubMed ID: 16771759
[TBL] [Abstract][Full Text] [Related]
12. Use of cannabinoid derivatives in glaucoma.
Newell FW; Jay WM; Sternberg P
Trans Ophthalmol Soc U K (1962); 1979 Jul; 99(2):269-71. PubMed ID: 298426
[No Abstract] [Full Text] [Related]
13. Intraocular pressure-lowering activity of topical application of Aegle marmelos fruit extract in experimental animal models.
Agarwal R; Gupta SK; Srivastava S; Saxena R; Agrawal SS
Ophthalmic Res; 2009; 42(2):112-6. PubMed ID: 19556826
[TBL] [Abstract][Full Text] [Related]
14. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes.
Wang RF; Podos SM; Mittag TW; Yokoyoma T
Exp Eye Res; 2005 May; 80(5):629-32. PubMed ID: 15862169
[TBL] [Abstract][Full Text] [Related]
15. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.
Yee RW
Curr Opin Ophthalmol; 2007 Mar; 18(2):134-9. PubMed ID: 17301615
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma.
Gupta SK; Agarwal R; Galpalli ND; Srivastava S; Agrawal SS; Saxena R
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):665-71. PubMed ID: 18200329
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoids in the treatment of glaucoma.
Järvinen T; Pate DW; Laine K
Pharmacol Ther; 2002 Aug; 95(2):203-20. PubMed ID: 12182967
[TBL] [Abstract][Full Text] [Related]
19. Marijuana smoking vs cannabinoids for glaucoma therapy.
Green K
Arch Ophthalmol; 1998 Nov; 116(11):1433-7. PubMed ID: 9823341
[TBL] [Abstract][Full Text] [Related]
20. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model.
Seki M; Tanaka T; Matsuda H; Togano T; Hashimoto K; Ueda J; Fukuchi T; Abe H
Br J Ophthalmol; 2005 Apr; 89(4):504-7. PubMed ID: 15774933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
